Lantheus Holdings, Inc.

Good morning. Welcome to Lanthea's first quarter 2025 conference call. All lines have been placed on mute. This call is being recorded and a replay will be available in the investor section of the company's website approximately two hours after the completion of the call and will be archived for at least 30 days. I'll now turn the call over to Mark Canarni, Vice President of Investor Relations. Mark?

Thank you. Good morning. With me today are Brian Markison, our CEO, Paul Blanchfield, our President, Bob Marshall, our CFO, and Amanda Morgan, our Chief Commercial Officer. We will begin with prepared remarks and then take your questions. This morning, we issued a press release which was furnished to the SEC under Form 8K, reporting our first quarter 2025 results. The release and today's slide presentation are available in the investor section of our website. Any comments made could include forward-looking statements. Actual results may differ materially from these statements due to a risk, due to a variety of risks and uncertainties which are detailed in our SEC filings. Discussions will also include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures is included in the investor section of our website. I will now turn the call over to our CEO, Brian.

Thank you, Mark. And good morning, everyone. Before I dive into my prepared remarks, I'd like to note our press release from last evening where we announced our plans to divest our spec business to Shine Technologies. I would like to extend my heartfelt thanks to the incredible team that has been with the company from the very beginning and has played a vital role in shaping Lantheus into what it is today. In 2025, we've been laying the foundation for the next chapter of our business. We announced two acquisitions in the first quarter, Evergreen Theranostics and Life Molecular Imaging. Both are designed to fuel our radiopharmaceutical leadership and sustain long-term growth. We closed on Evergreen in early April and expect to close the LMI acquisition in the coming weeks. And as I mentioned, we also announced an agreement to vest our spec business. Collectively, these transactions accomplish a number of objectives. First, they add immediate revenue growth drivers that complement our business and diversify our revenue. Second, they add exciting programs in late and early stage development. Third, they add key capabilities, both people and infrastructure, that will enable the company to deliver novel programs from bench to clinic, and ultimately patients. And finally, they streamline and help focus our organization. This year, we are focused on integrating the Evergreen and LMI businesses and finalizing the divestment of our SPECT business. With our strong cash position and disciplined capital allocation strategy, we are well positioned to continue investing in our capabilities, advancing and selectively expanding our pipeline, and returning value to shareholders. With that, I'll turn the call over to Paul to give an operational and strategic update.